SOPHiA GENETICS SA (NASDAQ:SOPH) Sees Large Drop in Short Interest

SOPHiA GENETICS SA (NASDAQ:SOPH) was the recipient of a significant decrease in short interest in January. As of January 31st, there was short interest totalling 19,800 shares, a decrease of 34.0% from the January 15th total of 30,000 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily volume of 53,500 shares, the short-interest ratio is currently 0.4 days.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Dimensional Fund Advisors LP boosted its stake in SOPHiA GENETICS by 23.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 21,619 shares of the company’s stock valued at $68,000 after buying an additional 4,115 shares in the last quarter. Silverberg Bernstein Capital Management LLC acquired a new stake in SOPHiA GENETICS in the fourth quarter valued at approximately $70,000. Green Alpha Advisors LLC increased its position in shares of SOPHiA GENETICS by 119.3% during the fourth quarter. Green Alpha Advisors LLC now owns 47,216 shares of the company’s stock worth $145,000 after acquiring an additional 25,686 shares in the last quarter. Federated Hermes Inc. raised its position in SOPHiA GENETICS by 40.5% in the 4th quarter. Federated Hermes Inc. now owns 100,000 shares of the company’s stock valued at $312,000 after buying an additional 28,819 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of SOPHiA GENETICS by 6.3% in the 3rd quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company’s stock worth $5,290,000 after buying an additional 86,764 shares during the last quarter. Institutional investors and hedge funds own 31.59% of the company’s stock.

SOPHiA GENETICS Stock Up 0.5 %

Shares of SOPHiA GENETICS stock opened at $3.82 on Friday. SOPHiA GENETICS has a 1 year low of $2.70 and a 1 year high of $7.37. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.80 and a quick ratio of 3.59. The business has a 50-day moving average of $3.41 and a two-hundred day moving average of $3.56. The company has a market capitalization of $249.69 million, a P/E ratio of -3.60 and a beta of 1.03.

Analyst Ratings Changes

Separately, Craig Hallum started coverage on SOPHiA GENETICS in a research report on Wednesday, December 18th. They issued a “buy” rating and a $11.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $7.40.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.